Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Break Above 50-Day Moving Average – Here’s What Happened

Posted by Brian Himes on Nov 11th, 2026

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) passed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $1.80 and traded as high as $1.9178. Lexicon Pharmaceuticals shares last traded at $1.82, with a volume of 2,560,531 shares traded.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on LXRX shares. Cantor Fitzgerald started coverage on Lexicon Pharmaceuticals in a report on Monday, September 28th. They set an “overweight” rating and a $8.00 price target for the company. Citigroup raised their price objective on shares of Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the stock a “buy” rating in a research note on Monday. Zacks Research lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Wall Street Zen raised shares of Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Sunday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Wednesday, October 21st. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.80.

Read Our Latest Stock Analysis on LXRX

Lexicon Pharmaceuticals Stock Up 0.5%

The stock has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $1.89. The company has a quick ratio of 10.56, a current ratio of 10.62 and a debt-to-equity ratio of 0.32.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The business had revenue of $11.25 million for the quarter, compared to analysts’ expectations of $4.14 million. Lexicon Pharmaceuticals had a negative return on equity of 35.76% and a negative net margin of 161.80%. On average, equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.16 EPS for the current year.

Insider Buying and Selling

In other Lexicon Pharmaceuticals news, CEO Michael Exton purchased 30,064 shares of the firm’s stock in a transaction on Friday, November 6th. The shares were purchased at an average price of $1.66 per share, for a total transaction of $49,906.24. Following the completion of the purchase, the chief executive officer directly owned 328,496 shares of the company’s stock, valued at approximately $545,303.36. This represents a 10.07% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

A number of hedge funds have recently made changes to their positions in LXRX. Bank of New York Mellon Corp lifted its holdings in shares of Lexicon Pharmaceuticals by 43.6% during the 1st quarter. Bank of New York Mellon Corp now owns 27,459 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 8,335 shares during the period. Squarepoint Ops LLC bought a new stake in Lexicon Pharmaceuticals in the second quarter valued at about $28,000. CTC Alternative Strategies Ltd. bought a new stake in Lexicon Pharmaceuticals in the first quarter valued at about $27,000. WINTON GROUP Ltd increased its stake in Lexicon Pharmaceuticals by 69.4% in the second quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 17,700 shares during the period. Finally, Pictet Asset Management Holding SA acquired a new position in Lexicon Pharmaceuticals in the third quarter worth about $41,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

(Get Free Report)

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.